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Renal replacement therapy by hemodialysis, peri-
toneal dialysis, or renal transplantation prolongs survival
in patients with end-stage renal disease (ESRD) and, in
most cases, provides a good quality of life. In all rich coun-
tries, new dialysis patients outnumber those who die, and
the group of patients on renal replacement therapy is
growing. The provision of adequate treatment to all is ab-
sorbing a large proportion of the health care budget and
is being looked at with concern by policymakers. Since
rationing of dialysis or deciding that some patients can-
not be treated is out of the question, clinicians should be
looking for ways to prevent the need for dialysis in as
many patients as possible.
THE CONCEPT OF RENOPROTECTION
There is robust experimental evidence that protein-
uria is responsible for interstitial inflammation and subse-
quent fibrosis, thereby contributing to progressive renal
function loss [1]. In chronic proteinuric nephropathies, if
the interstitial inflammatory reaction and the subsequent
fibrosis is indeed a feature of protein overloading, limiting
protein traffic or the biological effect of excessive tubular
protein reabsorption should prevent or slow the progres-
sion of renal disease. This is precisely what happens in
animals treated with angiotensin-converting enzyme in-
hibitors (ACE-i). The experimental demonstration that
the blockade of angiotensin II with ACE-i slowed the
progressive loss of renal function in a number of animal
models of renal diseases, including diabetic nephropathy
[2, 3], offered the opportunity, for the first time, to devise
a treatment strategy that was not limited to passively ac-
companying patients to their destiny of dialysis, but was
aimed at preserving renal function as long as possible.
The concept of renoprotection has then emerged.
Clinical studies and clinicopathologic correlations in
patients with progressive nephropathies indicate that the
observations in experimental models are relevant to un-
derstanding human disease [4]. Researchers identified
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an important correlation between urinary protein ex-
cretion and rate of glomerular filtration rate (GFR) de-
cline in patients with diabetic [5] and nondiabetic chronic
nephropathy [6]. The role of proteinuria as a strong, in-
dependent predictor of ESRD has been also recently
documented in a mass screening setting [7]. By screen-
ing more than 100,000 healthy individuals in 1983 in
Okinawa, Japan, and following them for up to 17 years,
a positive relationship was found between baseline pro-
teinuria (by dipstick urine test) and the risk of developing
ESRD. Even a slight increase in proteinuria was an inde-
pendent risk factor for ESRD. Moreover, the predictive
value of the protein excretion rate was independent of
the baseline GFR levels [abstract; Iseki K et al, J Am Soc
Nephrol 14:194A, 2003].
Whenever proteinuria is decreased, progression to
ESRD is reduced [8, 9–11]. Results of the Modification of
Diet in Renal Disease (MDRD) study [8] established that
a reduction of proteinuria was associated with a decrease
in the rate of decline in GFR, and that the protection
of renal function achieved by lowering blood pressure
was dependent on the extent of initial proteinuria. The
role of proteinuria as a promoter of progression, and
its impact on renal outcome, was also explored by the
Ramipril Efficacy in Nephropathy (REIN) study [11].
This study was designed to assess the hypothesis that
ACE inhibition could be superior to other antihyperten-
sive drugs in reducing proteinuria, limiting the decline
in GFR, and preventing ESRD in patients with chronic
nephropathies. In this study, patients were randomly as-
signed to receive ramipril or conventional antihyperten-
sive therapy to maintain diastolic blood pressure at 90 mm
Hg or less. A prestratification strategy recognized 2 levels
of proteinuria (stratum 1: >1 and <3 g/24 hours; stratum
2: ≥3 g/24 h). The study showed that while blood pres-
sure control was similar in the 2 treatment groups, ACE
inhibitor therapy decreased the progression to ESRD
by 50% [11, 12]. Patients who had more proteinuria to
start with benefited more from blood pressure-lowering
treatment than those who had less proteinuria. A meta-
analysis [abstract; Jafar TH et al, J Am Soc Nephrol
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11:63A, 2000] in 1860 patients with chronic nephropathies
also recorded that the benefit of ACE inhibition was
greatest in patients with high urine protein excretion at
baseline. This drug class seems to have a greater antipro-
teinuric effect than do other antihypertensive drugs, de-
spite equal effects on blood pressure: the investigators
concluded that proteinuria is the most important modi-
fiable risk factor to slow progression, and that reduction
of urine protein excretion is the main goal for treatment.
The REIN study was continued for 2 years (the REIN
follow-up study), during which period all patients previ-
ously on placebo were switched to ACE inhibitor [12].
In patients continuing to receive ramipril, GFR decline
rate further decreased to approximately 1 mL/min year
during follow-up, a figure similar to that associated with
normal aging. Patients who switched from conventional
therapy to ramipril also benefited from treatment. One of
the most impressive findings of this prolonged follow-up
was that after about 36 months of treatment with ramipril,
no additional patients progressed to the point of requir-
ing dialysis, whereas patients switched from conventional
therapy to ramipril continued to develop ESRD. To fur-
ther investigate the nature of the time-dependent im-
provement in GFR change, a break point in the individual
GFR slopes of patients receiving continued ramipril ther-
apy was sought. It could be predicted that after the break
point, 10 patients receiving continued ramipril therapy
would never progress to ESRD, and that 10 had such im-
proved GFR slopes that progression to ESRD would be
delayed by about 5 years. The analysis provides evidence
that the tendency of GFR to decline with time can be
halted and remission is achievable in some patients with
chronic renal disease.
The decade of large clinical trials in nephropathy was
closed when the results of 3 important studies were pub-
lished in the New England Journal of Medicine [13–15].
All 3 studies examined the role of ARBs in type 2 diabetic
nephropathy. One study evaluated the renoprotective ef-
fect of ARB irbesartan in hypertensive patients with in-
cipient nephropathy [15]. The end point of the study was
the time of onset of overt albuminuria. In 2 years of
follow-up, only 5.2% of patients receiving 300 mg of irbe-
sartan reached the end point compared with 14.9% of pa-
tients on placebo. The groups had similar blood pressure
control, a finding that suggests that ARBs are renoprotec-
tive independently of their antihypertensive effect. The
role of ARB in overt diabetic nephropathy was explored
in 2 other trials published in 2001 [13, 14]. In both studies,
treatment with ARB resulted in a significant reduction of
proteinuria, the incidence of doubling serum creatinine,
and the risk of ESRD.
Although we have limited our review to only a few
clinical studies, several other trials have been published,
some of them small in size, with little statistical power, and
with short follow-up. However, they all point in one direc-
tion: blockade of renin-angiotensin system is beneficial in
most chronic nephropathies. This may be not true in overt
nephropathy of type 2 diabetes. The results of several clin-
ical trials have shown, with one exception, that no signif-
icant difference was found in terms of renoprotection, as
measured as prevention of GFR decline over time, be-
tween ACE inhibitors and other antihypertensive agents
[16]. Indeed, in patients with type 2 diabetic nephropa-
thy, overt proteinuria, and renal insufficiency, an ACE
inhibitor was not able to modify renal hemodynamics
and glomerular sieving properties, despite effective blood
pressure control [17]. Nevertheless, recent evidence has
documented that the use of ACE inhibitors was associ-
ated with a significant reduction in all-cause (adjusted
hazard ratio: 0.49; 95% CI 0.40–0.61) and cardiovascular-
related (adjusted hazard ratio: 0.63; 95% CI 0.44–0.90)
mortality in a broad spectrum of 6176 patients with type
2 diabetes and no cardiovascular disease [18]. The study
estimated that for every 12 of the diabetics with no signs of
heart or blood pressure problems given ACE inhibitors,
after about 4 years 1 death was prevented. In summary,
currently available treatments have uniformly shown that
reduction of blood pressure per se is beneficial in pa-
tients with type 2 diabetic nephropathy, while the effect
of renin-angiotensin system blockade is probably less rel-
evant than in type 1 diabetic nephropathy or nondiabetic
nephropathies. Nevertheless, the results of the last decade
of experiments and trials are an important platform of
knowledge to devise the best strategy in preventing dia-
betic nephropathy in the next 10 years.
MORE RENOPROTECTION WITH
UP-TITRATION OF ACE INHIBITORS OR DUAL
BLOCKADE OF RAS
Although encouraging, evidence from both experi-
mental studies and clinical trials suggests that RAS in-
hibition postpones ESRD in most cases, but definitively
prevents dialysis only in a minority of patients. Indeed, as
a result of the current lag time between starting treatment
and achievement of remission, a substantial proportion of
patients still progresses to ESRD before their renal func-
tion begins to stabilize. ACEi alone is sufficient to halt
progression if therapy is started early, at GFRs still higher
than 50 mL/min/1.73m2. To achieve this target at more
advanced stages, a multimodal approach based on maxi-
mized RAS inhibition is needed. First, a low-sodium diet
could serve to activate the intrarenal RAS, which would
maximize the response to ACEi or ARBs. Diuretics could
also achieve this, in particular when the response to RAS
inhibition is blunted by sodium retention secondary to a
high-sodium diet and/or severe renal insufficiency. How-
ever, maximized RAS inhibition mainly rests on the use
of higher than antihypertensive doses of ACEi or ARBs
or of these 2 agents in combination. Lisinopril up-titrated
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to 40 mg/day (twice the standard antihypertensive dose
for patients with normal renal function), despite no ad-
ditional effects on blood pressure, further reduced pro-
teinuria and, importantly, dose dependently ameliorated
the dyslipidemia associated with the nephrotic syndrome
[19].
Complementary or alternative to forced ACEi or
ARBs up-titration is combined treatment with both
agents [20, 21]. The combination of an ACEi and ARBs
has been suggested as a way to maximize RAS blockade
by affecting both the bioavailability of Ang II through
ACEi, and also by affecting its activity at the receptor
level. This approach has recently offered a powerful tool
to induce regression of renal disease at functional and
structural levels.
On the clinical grounds, several studies found more
proteinuria reduction with combined therapy than with
ACEi or ARBs alone [20, 21]. This effect, however, was
almost invariably associated with more blood pressure
reduction with combined therapy, which did not allow
concluding on whether the superior antiproteinuric ef-
fect of combined therapy depended on more RAS inhi-
bition rather than on more blood pressure reduction. To
dissect the relative contribution of these 2 mechanisms,
we recently compared the antiproteinuric effect of com-
bined therapy with halved doses of benazepril and val-
sartan with the effect of full doses of both agents used
alone [22]. The finding that combined therapy reduced
proteinuria more effectively than the 2 agents alone at
virtually identical levels of blood pressure control pro-
vided consistent evidence of the intrinsic renoprotec-
tive effect of combined RAS inhibition. The benefit of
combined therapy was more consistent, and clinically
relevant, in patients with more severe, nephrotic-range,
proteinuria. The superior, long-term renoprotective ef-
fect of combined versus single drug RAS inhibition was
confirmed by the results of the COOPERATE study [23].
This study included 263 patients with nondiabetic, pro-
teinuric nephropathies randomized to 3-year treatment
with 3 mg/day of trandolapril, 100 mg/day of losartan or
both drugs in combination. Eleven percent of patients on
combination treatment reached the combined primary
end point of doubling of serum creatinine concentra-
tion or ESRD compared with 23% of patients on tran-
dolapril alone (hazard ratio 0.38, 95% CI 0.18–0.63, P =
0.018) and 23% of those on losartan alone (0.40, 0.17–
0.69, P = 0.016). Thus, combined therapy reduced pro-
gression to the end point by about 60% compared to
single ACEi or ARB treatment. The most striking dif-
ference in groups was the much more consistent pro-
teinuria reduction (versus prerandomization values) on
dual RAS blockade (76%) than on single ACEi (44%)
or ARB (42%) treatment. The finding that the 3 treat-
ment groups did not differ with respect to risk factors and
showed the same reductions in blood pressure, combined
with evidence that improved kidney survival was strongly
associated with more proteinuria reduction, led further
support to the hypothesis that proteinuria reduction may
have an important pathogenetic role in the renoprotec-
tive effect of (dual) RAS blockade. Consistent with short-
term data [22], the greater the proteinuria at baseline, the
more the proteinuria reduction on follow-up [23]. Hence,
combined therapy was well tolerated, even in patients
with advanced renal insufficiency, which provided further
evidence that the practice of avoidance of ACEi, ARB,
or both to prevent further renal impairment and hyper-
kalemia in patients closer to ESRD is no longer justified
[24]. Although good, these results show that a substantial
proportion of patients with chronic nephropathies still
continues to progress even on combined treatment.
Although many studies demonstrate the usefulness of
ACEi and ARBs to delay the decline in renal function and
reduce proteinuria, many physicians fail to use these drug
classes in patients with renal insufficiency for fear that ei-
ther serum creatinine or potassium levels will increase.
Thus, because of these issues, patients are deprived of
known strategies that delay progression of renal disease.
However, in a pooled analysis of 6 published trials in-
cluding 1514 diabetic and nondiabetic patients with pro-
teinuric chronic nephropathies [10–12, 25–27], we have
found that the incidence of drop-outs because of uncon-
trolled hyperkalemia was similar and less than 2% in
both ACEi and conventional treatment group. Interest-
ingly, the REIN study [11] found that differences in serum
potassium levels between ramipril-treated patients and
controls never exceeded 0.3 mEq/L throughout the whole
follow-up period. Similar data can be derived (although
the numbers are small) from the analyses of studies on
ARBs alone or in combination with ACEi. Actually, risk
of hyperkalemia was minimized by excluding patients
with renovascular disease. Moreover, serum potassium
was closely monitored, hyperglycemia and metabolic aci-
dosis were carefully treated, and thiazidic or loop di-
uretics were frequently used in combination with ACEi.
Adherence to these simple guidelines is therefore recom-
mended to manage patients with drugs that inhibit the
RAS. In patients with renal insufficiency, ACEi therapy
is even more cardioprotective than in the general pop-
ulation and is well tolerated. Thus, a small rise in serum
creatinine level (<30%) is outweighed by improved long-
term renal survival.
A MULTIFACTORIAL INTERVENTION AS
ULTIMATE TREATMENT FOR THE
PROGRESSIVE RENAL DISEASE
A significant number of patients treated with ACEi/
ARB did show only partial antiproteinuric response, and
this heralds a progressive loss of renal function in most
cases [10, 11, 13–15, 24]. Thus, a multidrug approach
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may likely be the next improvement. This is some-
thing investigators are now currently exploring in for-
mal multicenter randomized trials, such as BENEDICT
(Bergamo Nephrologic Diabetes Complication Trial) and
DEMAND (Delapril and Manidipine for Nephropro-
tection in Diabetes). These are studies aimed to assess
whether, at comparable levels of optimal blood pres-
sure and metabolic control, ACE inhibitors alone or in
combination with a non-dihydropyridinic (BENEDICT)
or a novel dihydropyridinic (DEMAND) calcium chan-
nel blocker, respectively, reduce the albumin excretion
rate and slow GFR decline compared with placebo plus
conventional antihypertensive therapy in patients with
type 2 diabetes mellitus, hypertension, and normo- or
microalbuminuria. Intensive, multimodal approach to
the treatment of chronic nephropathies, which includes
BP control, inhibition of the RAS, glucose control, and
lipid control, should be more effective than standard ap-
proaches. Interest has been growing lately to the new
treatment modalities. Data presented at the 62nd Scien-
tific Session of the American Diabetes Association sug-
gested that the association of an aldosterone blocking
agent, eplerenone to enalapril, reduced microalbumin-
uria in type 2 diabetic patients to a greater extent than
each drug alone, although hyperkalemia was a cause of
withdrawal from the study for a significant number of pa-
tients [abstract; Buckalew V et al, Diabetes 51:38A, 2002].
Over the past several years, transforming growth factor-b
(TGF-b) has been recognized as a central player in the
fibrogenic process of diabetic nephropathy [28, 29] due
to its activity of both stimulating matrix production and
blocking matrix degradation [30, 31]. Experimental data
suggest that anti-TGF-b antibody added to a background
of chronic ACE inhibition therapy fully protects from the
development of proteinuria and renal injury of overt di-
abetic nephropathy [32]. Also, in a severe model of pro-
gressive nephropathy resistant to ACE-i, combining the
ACE-i with a statin arrests proteinuria and protects from
renal function and structure impairment [33].
The multidrug approach to chronic nephropathies has
been formalized in an interventional protocol that has
been named remission clinic [34]. Patients with chronic
kidney disease and proteinuria greater than 1 g/24 hours
are initially treated with a low starting dose of an ACE-i,
which is then increased up to the maximum dose. Then, if
the goals of blood pressure <120/80 mm Hg and protein-
uria <0.3 g/24 hours are not achieved, an ARB is added
at half-maximum dose. Again, the dose is increased step-
wise. Throughout this up-titration of ACE-i or ARB, the
addition of diuretics is usually needed for optimal blood
pressure control or prevention of hyperkalemia. If, after
this step target blood pressure and proteinuria are still
not achieved, the next antiproteinuric drug to be added
is usually a nondihydropiridinic calcium channel blocker.
In those with low-density lipoprotein (LDL) cholesterol
>100 mg/dL, a statin is added, and in those with diabetes,
glycemic control is reinforced to achieve hemoglobin A1c
(HbA1c) <7.5%. Both interventions (lipid reduction and
tight glycemic control) are supposed to contribute to
renoprotection [16, 35]. The multiple drug approach has
been tested in more than 40 patients in our unit, and we
could prove that is feasible and effective. However, it is
difficult to test in a formal study since any further addi-
tion of new or old drug to ACE-i or ARBs in a multiple
intervention trial would require a very large number of
subjects, and would be too costly for any company to sup-
port [36]. We probably should make better use of small
but well-designed and rigorously conducted study with
carefully selected marker of renal progression.
Looking for a more effective treatment, the role of
lifestyle changes should not be overlooked. Smoking ces-
sation, per se, may reduce disease progression by 30%,
which qualifies as the single most important renoprotec-
tive measure [37]. Physical activity has always been con-
sidered instrumental to the loss of excess weight, but it
may have an intrinsic favorable effect, as documented by
a small study in 20 patients with chronic kidney disease
who were assigned to 12-week regular aquatic exercise
or the armchair [38]. During this short period of time, the
body mass index did not change in either group. How-
ever, proteinuria decreased by 50% in those who per-
formed aquatic exercise, while it did not change in the
sedentary group. Limiting dietary protein is necessary to
prevent the accumulation of unexcreted waste products
that could cause the symptoms of uremia. In addition, a
high-protein diet generally contains an excess of lipids,
phosphates, acid, potassium, and other ions that could
be detrimental to patients with kidney disease. The in-
fluence of a low-protein diet on progression of renal in-
sufficiency is controversial, but meta-analysis indicates it
is helpful. A nutritionally sound diet that will maintain
protein balance and limit the accumulation of potentially
toxic compounds and ions contains 0.8 g protein/kg ideal
body weight/day. Maintaining this diet is possible with as-
sistance from a nutritionist and measuring the amount of
dietary protein.
The efficacy of the multifactorial intervention is sup-
ported by a target-driven, long-term (mean follow-up
7.8 years), intensified intervention aimed at multiple risk
factors in 80 patients with type 2 diabetes and microal-
buminuria, which reduced the risk of nephropathy and
cardiovascular and microvascular events by about 50%
[39].
CONCLUSION
The current therapeutic approach for proteinuric
chronic nephropathies is based on blockade of the renin-
angiotensin system with ACE-i and/or ARBs that limit
proteinuria, reduce GFR decline and risk of ESRD more
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effectively than other antihypertensive treatments. Full
remission of the disease, however, is seldom obtained,
particularly when pharmacologic intervention is started
late. For nonresponders, treatment procedure to remis-
sion and/or regression must include a multimodal strategy
to implement renoprotection.
Preventing nephropathy is, however, more important
than retarding progression, and this should be the next
step for the nephrologists. Nevertheless, so far, treatment
of renal patients has been aimed to limit or prevent pro-
gression to ESRD. While we are trying to reduce the
number of patients who reach the ESRD, the real prob-
lem is patients who actually die before end-stage renal
failure. Indeed, in more than 400,000 Medicare patients
with diabetes and chronic kidney disease, over 2 years
of follow-up, the risk of death (29%) far exceeded that
of developing ESRD (6%) [40]. This observation is con-
firmed by the analysis of the United Kingdom Prospective
Diabetes study (UKPDS 64), showing that among 5000
type 2 diabetics followed for up to 8 years, death due to
cardiovascular disease is far more common than devel-
opment of ESRD [41]. Thus, for the future, the goal will
be not only to concentrate on reducing the number of
patients who reach end-stage renal failure, but also on
those who are at risk of dying of myocardial infarction
or other cardiovascular diseases before they reach end-
stage renal failure. Why should nephrologists be involved
in that? Because these patients have usually microalbu-
minuria or some degree of renal dysfunction. From now
on, our efforts should be to find these patients and treat
them before they develop cardiac or brain accidents.
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